Angiogenic cytokine and interleukin 8 levels in early luteal phase after triggering ovulation with gonadotropin-releasing hormone agonist in high-responder patients

Am J Reprod Immunol. 2021 Jun;85(6):e13381. doi: 10.1111/aji.13381. Epub 2020 Dec 16.

Abstract

Problem: Interleukin 8 (IL-8), vascular endothelial growth factor A (VEGFA), its receptors 1 (VEGFR1) and 2 (VEGFR2) are associated with ovarian hyperstimulation syndrome (OHSS) pathophysiological mechanisms. The aim of this study was to evaluate the concentrations of these cytokines depending on the way of ovulation triggering.

Method of study: A total of 51 high-responder patients underwent IVF program and received gonadotropin-releasing hormone agonists (GnRHa) trigger + 1500 IU human chorionic gonadotropin (hCG) support on the oocyte pick-up (OPU) day (group I), dual trigger (GnRHa + 1500 IU hCG; group II), or hCG trigger 10,000 IU (group III) for the final oocyte maturation. The concentrations of cytokines were evaluated in serum by the enzyme-linked immunosorbent assay kit.

Result(s): VEGFR2 levels were significantly lower in groups I and II than in group III in serum on the OPU (I vs. III, p = .0456; II vs. III, p = .0122) and OPU + 5 day (I vs. III, p = .0004; II vs. III, p = .0082). VEGFA levels were lower in group I than in group III (p = .0298) on the OPU day, however, were similar in all groups on the OPU + 5 day.

Conclusion(s): A small dose of hCG elicits similar concentrations of VEGFA to a full dose of hCG; however, GnRHa triggering reduces the concentrations of VEGFR2, which could lead to the OHSS prevention.

Keywords: GnRH agonist trigger; IL-8; VEGF; VEGF receptor 1; VEGF receptor 2; dual trigger.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Chorionic Gonadotropin / therapeutic use*
  • Female
  • Fertilization in Vitro
  • Gonadotropin-Releasing Hormone / agonists*
  • Humans
  • Interleukin-8 / blood*
  • Luteal Phase / drug effects
  • Luteolytic Agents / therapeutic use*
  • Ovulation / drug effects
  • Triptorelin Pamoate / therapeutic use*
  • Vascular Endothelial Growth Factor A / blood*
  • Vascular Endothelial Growth Factor Receptor-1 / blood*
  • Vascular Endothelial Growth Factor Receptor-2 / blood*

Substances

  • Chorionic Gonadotropin
  • Interleukin-8
  • Luteolytic Agents
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Triptorelin Pamoate
  • Gonadotropin-Releasing Hormone
  • KDR protein, human
  • Vascular Endothelial Growth Factor Receptor-1
  • Vascular Endothelial Growth Factor Receptor-2